🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07351812
Recruiting Not applicable

Two Treatment Modalities for Myogenous Temporomandibular Disorders

NCT07351812 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-01
Last updated
2026-01-20

Condition(s) studied

TMD

Investigational drug(s) / intervention(s)

Stabilization ApplianceEar Stent

Stabilization Appliance: Participants will receive a maxillary stabilization appliance fabricated from 2-mm hard thermoplastic material using diagnostic casts. The appliance fit will be verified, and patients will be instructed to wear it for 3 months.

Ear Stent: Participants will undergo ENT evaluation prior to ear impression taking. Custom ear stents will be fabricated from soft addition silicone and hollowed to prevent hearing impairment.

Study summary

Temporomandibular disorder (TMD) is a common condition with multifactorial etiology, including trauma, emotional stress, parafunctional habits, and occlusal discrepancies. TMD may be classified as myogenous, involving the masticatory and cervical muscles, or arthrogenous, affecting the temporomandibular joint structures. Management approaches range from noninvasive to invasive methods. The intraoral stabilization appliance (SA) is a widely used noninvasive treatment, while the ear stent (ES) has recently been introduced for managing myogenous TMD.

Aim: This randomized clinical trial aims to compare the effectiveness of SA and ES in the management of myogenous TMD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Participants presenting with pain score grading at least 4 out of 10 on NRS. * Participants with fully dentate type I occlusion. * Patients experiencing no neurological disorders. Exclusion Criteria: * Patients with arthrogenous TMJ will be excluded by Magnetic Resonance Imagining (MRI) * Patients who have clicking or crepitation. * Previous history of TMD treatment. * History of recent trauma. * The presence of systemic diseases (i.e., rheumatoid arthritis, osteoarthritis myologic or arthrological disease). * Vascular disease (migraine and hypertension). * Participants with uncontrolled systemic disease (diabetes), hematologic or neurologic disorders or inflammatory diseases. * Patients who: Underwent trigger point myofascial injection, intramuscular stimulation, or dry needling in the last six months or Underwent neck and/or shoulder surgery in the last year.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Alexandria Faculty of Dentistry Alexandria Egypt Recruiting

More Alexandria University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07351812 on ClinicalTrials.gov ↗ ← All trials in Egypt